Saturday (27.10.2018)

08:45 – 10:15

Room: Martin & Augustin
(Dorint Hotel)

Workshop Radiotherapy in Salvage

  • Simone Marnitz-Schulze
  • Joachim Yahalom
  • 08:45–09:00

    Radiotherapy for Salvage – Principles and ILROG Guidelines

    • Louis Constine
  • 09:00–09:15

    Radiotherapy techniques for salvage and re-irradiation

    • Bouthaina Dabaja
  • 09:15–09:30

    Long-term considerations in salvage therapy

    • Lena Specht
  • 09:30–09:45

    Radiation- and immunotherapy for relapsed or refractory HL

    • Christian Baues
  • 09:45–10:00

    Future of RT in Salvage – new approaches, alternatives to High Dose Chemotherapy

    • Joachim Yahalom
  • 10:00–10:15

    Panel Discussion

    • Simone Marnitz-Schulze
    • Joachim Yahalom

08:45 – 10:15

Room: Kleiner Saal

Workshop Molecular Pathogenesis

  • Martin-Leo Hansmann
  • Christian Steidl
  • 08:45–09:05

    Somatic gene mutations in NLPHL and THRLBCL

    • Sylvia Hartmann
    • Bianca Schuhmacher
  • 09:05–09:25

    Microenvironment biology and outcome prediction in pediatric Hodgkin Lymphoma

    • Anja Mottok
  • Abstract Talk

    CK2A is overexpressed, active and targetable with silmitasertib In classical Hodgkin Lymphoma

      Andrea Visentin
  • Abstract Talk

    Low B-cell content at diagnosis is associated with adverse outcome in advanced stage classical Hodgkin Lymphoma

      Wolfram Klapper
  • Abstract Talk

    ROR-1 receptor is a potential therapeutic target in classical Hodgkin Lymphoma

      George Rassidakis

08:45 – 10:15

Room: Marsilius Saal

Workshop Developing Health Care Environments

  • Anton Hagenbeek
  • Oliver Henke
  • 08:45–09:05

    Challenges at a Developing Cancer Center in East Africa

    • Oliver Henke
  • 09:05–09:25

    Takeda Access to Medicine Program in Subsaharan Africa

    • Judith Kinley
  • 09:25–09:45

    Hodgkin Lymphoma Care in Current Venezuela

    • Maria Alejandra Torres Viera
  • 09:45–10:15

    Panel Discussion

    • Anton Hagenbeek
    • Oliver Henke

08:45 – 10:15

Room: Großer Saal

Workshop PET

  • Markus Dietlein
  • Michel Meignan
  • 08:45–09:15

    PET / CT – The perspective from the German Hodgkin Study Group

    • Carsten Kobe
  • 09:15–09:45

    PET guided strategy in Hodgkin lymphoma: issues and perspectives

    • Andrea Gallamini
  • 09:45–10:15

    Measurement of metabolic volume and threshold in Hodgkin Lymphoma: how to move to a standard

    • Olivier Casasnovas

10:30 – 12:00

Room: Kleiner Saal

Workshop Survivorship

  • Ananda Plate
  • Flora van Leeuwen
  • 10:30–10:45

    Genetic determinants of radiation-induced breast cancer after HL

    • Flora van Leeuwen
  • 10:45–11:00

    Genetic polymorphisms associated with anthracycline-induced cardiotoxicity

    • Leszek Wojnowski
  • 11:00–11:15

    Genetic determinants for acute radiation toxicity

    • Catharine West
  • 11:15–11:30

    Genetic susceptibility for treatment-related adverse effects: How can we make signi cant progress?

    • Lindsay Morton
  • 11:30–12:00

    Panel Discussion

10:30 – 12:00

Room: Großer Saal

Workshop Immunotherapy: Chances & Pitfalls

  • Philippe Armand
  • Tim Illidge
  • 10:30–11:00

    The role of radiotherapy for Hodgkin Lymphoma in the era of PD-1 blockade

    • Tim Illidge
  • 11:00–11:30

    Impact of PD-1 blockade on the treatment landscape of Hodgkin Lymphoma

    • Philippe Armand
  • 11:30–12:00

    Pitfalls in clinical trial design and interpretation with immunotherapy

    • Stephen Ansell

10:30 – 12:00

Room: Marsilius Saal

Workshop Challenges in older Lymphoma Patients

  • Pauline Brice
  • Jonathan Friedberg
  • 10:30–10:45

    The role of geriatric assessments in lymphoma

    • Alessandra Tucci
  • 10:45–11:00

    Chemotherapy combinations in elderly HL

    • Pauline Brice
  • 11:00–11:15

    German experience in elderly HL

    • Boris Böll
  • 11:15–11:30

    Brentuximab combinations in elderly HL, including checkpoint inhibitor

    • Jonathan Friedberg
  • 11:30–11:45

    Brentuximab / chemotherapy combinations in elderly HL

    • Andrew Evens
  • 11:45–12:00

    Panel Discussion

    • Pauline Brice
    • Jonathan Friedberg

10:30 – 12:00

Room: Martin & Augustin
(Dorint Hotel)

Workshop Minimum Residual Disease

  • Anton Hagenbeek
  • Pier Luigi Zinzani
  • 10:30–10:50

    Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in FL

    • Marie-Hélène Delfau-Larue
  • 10:50–11:10

    The role of ctDNA in research and decision making-Lessons from ctDNA in DLBCL

    • Mark Roschewski
  • 11:10–11:30

    The Hodgkin Lymphoma MRD consortium

    • Sven Borchmann
    • Michiel Pegtel
  • 11:30–12:00

    Panel discussion

    • Anton Hagenbeek
    • Pier Luigi Zinzani

12:15 – 13:45

Room: Großer Saal

Scientific Symposium (by Sandoz Germany) Biosimilar rituximab – a new treatment option

  • Andreas Engert
  • 12:15–12:45

    Biosimilar Development in Oncology

    • Theodor Dingermann
  • 12:45–13:15

    Clinical evidence for biosimilar rituximab

    • Bertram Glaß
  • 13:15–13:45

    Treatment of CD20 positive, lymphocyte-predominant Hodgkin lymphoma

    • Dennis Eichenauer

14:00 – 15:30

Room: Großer Saal

Scientific Session Immunotherapy – Biomechanisms

  • Andreas Rosenwald
  • Margaret Shipp
  • 14:00–14:20

    T-cells and PD1 Inhibition in cHL

    • Margaret Shipp
  • 14:20–14:40

    Immune-Evasion

    • Maher K. Gandhi
  • Abstract Talk

    Expression of PD-1 and PD-L1 increase in multiple consecutive biopsies in patients with classical Hodgkin lymphoma

      Ingrid Glimelius
  • Abstract Talk

    Trabectedin inhibits classical Hodgkin Lymphoma growth, monocytes immunosuppressive polarization by tumor cells and synergizes with the CCR5-antagonist Maraviroc

      Naike Casagrande
  • Poster Pitch

    Development of an α-CD30 Bispecific Antibody Immunotherapy for Hodgkin Lymphoma

      Cindy Schwartz
  • Abstract Talk

    The peripheral blood Neutrophil PD-L1 and lymphocyte PD-1 axis in classical Hodgkin lymphoma at diagnosis

      Annarosa Cuccaro
  • Abstract Talk

    PD-L1+ and IDO-1+ tumor-associated macrophages predict survival in primary classical Hodgkin lymphoma

      Kristiina Karihtala

16:00 – 17:30

Room: Großer Saal

Scientific Symposium (by Takeda Oncology) Advanced HL: How Can We Do Better?

  • Mark Hertzberg
  • 16:00–16:10

    Introduction: Brief overview of key milestones in HL management over recent years

    • Mark Hertzberg
  • 16:10–16:30

    Can we do better in front-line?

    • Astrid Pavlovsky
  • 16:30–16:35

    iPad Audience Q&A with panel discussion

  • 16:35–16:55

    Can we do better with salvage?

    • Craig H. Moskowitz
  • 16:55–17:00

    iPad Audience Q&A with panel discussion

  • 17:00–17:20

    Can we do better in assessing risk of failure throughout the patient journey?

    • Martin Hutchings
  • 17:20–17:25

    iPad Audience Q&A with panel discussion

  • 17:25–17:30

    Chairman’s wrap-up

    • Mark Hertzberg

17:45 – 19:15

Room: Großer Saal

Main Program Opening Ceremony

  • Introduction and Welcome from the Symposium Chairman

    • Andreas Engert
  • Welcoming Address

    • Volker Diehl
  • Welcoming Address

    • Stefan Herzig
  • Key Note Lecture: The role of patient advocacy and patient involvement in research

    • Jan Geissler
  • Awards Ceremony

19:45

Room: Weinkeller

Main Program Welcome Reception

ISHL11 Final Program

ISHL11 Final Program

ISHL11 Program at a glance

ISHL11 Program at a glance